Literature DB >> 8258416

Hepatic peroxisome proliferation in rodents and its significance for humans.

P Bentley1, I Calder, C Elcombe, P Grasso, D Stringer, H J Wiegand.   

Abstract

Peroxisomes are subcellular organelles found in all eukaryotic cells. In the liver they are usually round and measure about 0.5-1.0 microns; in rodents they contain a prominent crystalloid core, but this may be absent in newly formed rodent peroxisomes as well as in human peroxisomes. A major role of the peroxisomes is the breakdown of long-chain fatty acids, thereby complementing mitochondrial fatty-acid metabolism. Many chemicals are known to increase the number of peroxisomes in rat and mouse hepatocytes. This peroxisome proliferation is accompanied by replicative DNA synthesis and liver growth. No clear structure-activity relationships are apparent. Many of these peroxisome proliferators contain acid functions that can modulate fatty acid metabolism. Two mechanisms have been proposed for the induction of peroxisome proliferation. One is based on the existence of one or several specific cytosolic receptors that bind the peroxisome proliferator, facilitating its translocation to the cell nucleus and the activation of the expression of specific genes. The second, perhaps more general, hypothesis involves chemically mediated perturbation of lipid metabolism. These two hypotheses are not mutually exclusive. Many peroxisome proliferators have been shown to induce hepatocellular tumours, despite being uniformly non-genotoxic, when administered at high dose levels to rats and mice for long periods. Three mechanisms have been proposed to explain the induction of tumours. One is based on increased production of active oxygen species due to imbalanced production of peroxisomal enzymes; it has been proposed that these reactive oxygen species cause indirect DNA damage with subsequent tumour formation. In rodents, an alternative mechanism is the promotion of endogenous lesions by sustained DNA synthesis and hyperplasia. Thirdly, it is conceivable that sustained growth stimulation may be sufficient for tumour formation. Marked species differences are apparent in response to peroxisome proliferations. Rats and mice are extremely sensitive, and hamsters show an intermediate response while guinea pigs, monkeys and humans appear to be relatively insensitive or non-responsive at dose levels that produce a marked response in rodents. These species differences may be reproduced in vitro using primary culture hepatocytes isolated from a variety of species including humans. The available experimental evidence suggests a strong association and a probable casual link between peroxisome-proliferator-elicited liver growth and the subsequent development of liver tumours in rats and mice. Since humans are insensitive or unresponsive, at therapeutic dose levels, to peroxisome-proliferator-induced hepatic effects, it is reasonable to conclude that the encountered levels of exposure to these non-genotoxic agents do not present a hepatocarcinogenic hazard to humans.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258416     DOI: 10.1016/0278-6915(93)90225-n

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  34 in total

1.  4',6-Dimethoxyisoflavone-7-O-β-D-glucopyranoside (wistin) is a peroxisome proliferator-activated receptor α (PPARα) agonist in mouse hepatocytes.

Authors:  Misato Suzuki; Fumiya Nakamura; Emi Taguchi; Maho Nakata; Fumi Wada; Momoka Takihi; Tomoyo Inoue; Shinji Ohta; Hiroyuki Kawachi
Journal:  Mol Cell Biochem       Date:  2018-01-09       Impact factor: 3.396

2.  Dietary docosahexaenoic acid has little effect on peroxisomes in healthy mice.

Authors:  D De Craemer; M Pauwels; C Van den Branden
Journal:  Lipids       Date:  1996-11       Impact factor: 1.880

3.  Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis.

Authors:  Keiichirou Morimura; Connie Cheung; Jerrold M Ward; Janardan K Reddy; Frank J Gonzalez
Journal:  Carcinogenesis       Date:  2005-12-24       Impact factor: 4.944

Review 4.  Distinct but complementary contributions of PPAR isotypes to energy homeostasis.

Authors:  Vanessa Dubois; Jérôme Eeckhoute; Philippe Lefebvre; Bart Staels
Journal:  J Clin Invest       Date:  2017-04-03       Impact factor: 14.808

5.  A critical role for peroxisomal proliferator-activated receptor-alpha nuclear receptors in the development of cardiomyocyte degeneration and necrosis.

Authors:  Ingrid Pruimboom-Brees; Mehrdad Haghpassand; Lori Royer; Dominique Brees; Charles Aldinger; William Reagan; Jatinder Singh; Roy Kerlin; Christopher Kane; Scott Bagley; Cheryl Hayward; James Loy; Peter O'Brien; Omar L Francone
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

6.  The evidence on trial: cholesterol lowering and cancer.

Authors:  A M Tonkin; A Forbes; S J Haas
Journal:  Heart Asia       Date:  2009-01-01

Review 7.  Fibrates, glitazones, and peroxisome proliferator-activated receptors.

Authors:  Fanny Lalloyer; Bart Staels
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05       Impact factor: 8.311

8.  A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans.

Authors:  Katsutoshi Yoshizato; Chise Tateno
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

9.  The Role of PPARα Activation in Liver and Muscle.

Authors:  Lena Burri; G Hege Thoresen; Rolf K Berge
Journal:  PPAR Res       Date:  2010-08-18       Impact factor: 4.964

10.  Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid.

Authors:  M W Wilson; L T Lay; C K Chow; H H Tai; L W Robertson; H P Glauert
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.